Back

Immune receptor LAG3 regulates microglia function duringAlzheimer's disease

Perl, A. T.; Wu, J.; Dong, J. D.; Brooks, A. M.; Yoblinski, A. R.; Vierling, T. T.; Li, J.-L.; Ruby, D. R.; Radzicki, D.; Dudek, S. M.; Cushman, J. D.; Gjoneska, E.

2026-05-12 neuroscience
10.64898/2026.05.08.723911 bioRxiv
Show abstract

Alzheimers Disease (AD) remains the leading cause of dementia globally, yet the exact etiology is not well defined and effective treatments remain unavailable. Here, we report that deletion of the immune checkpoint receptor lymphocyte activation gene 3 (Lag3) in a familial AD mouse model, 5xFAD+, can rescue molecular, cellular and behavioral phenotypes of neurodegeneration. Specifically, we demonstrate that amyloidosis and microgliosis in the 5xFAD+ mice are significantly reduced by Lag3 deletion. Moreover, we show that Lag3 deletion attenuates deficits in neurodegeneration-related behavioral phenotypes in the 5xFAD+ mice. Transcriptional profiling reveals that Lag3 deletion suppresses aberrant overexpression of disease associated microglia (DAM) genes in 5xFAD+ microglia, effectively restoring homeostatic transcriptional programs. Finally, we observe reduced CD8+ T cell infiltration in the brain of 5xFAD+ animals after Lag3 deletion which likely mediates molecular, cellular and behavioral effects resulting from microglia DAM gene activation. Our results highlight a previously unrecognized role for Lag3 in AD as a critical regulator of microglia function and suggest Lag3 might be a viable target for novel AD therapeutic interventions. HighlightsO_LIImmune receptor Lag3 deletion ameliorates amyloidosis and microgliosis during AD C_LIO_LILag3 deletion attenuates deficits in neurodegeneration-related behavioral phenotypes C_LIO_LILag3 deletion reverses aberrant activation of DAM genes and restores microglia homeostasis C_LIO_LILag3 inhibition presents a viable approach for novel AD therapeutic interventions C_LI

Published in Neurobiology of Disease (predicted rank #4) · training set

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Alzheimer's & Dementia
14 papers in training set
Top 0.1%
9.4%
2
Acta Neuropathologica
58 papers in training set
Top 0.1%
9.4%
3
Alzheimer's & Dementia
163 papers in training set
Top 0.9%
5.3%
Neurobiology of Disease · published here
148 papers in training set
Top 0.7%
5.3%
5
Acta Neuropathologica Communications
89 papers in training set
Top 0.4%
5.3%
6
Journal of Neuroinflammation
61 papers in training set
Top 0.3%
5.3%
7
Molecular Neurodegeneration
55 papers in training set
Top 0.4%
4.7%
8
Nature Communications
5641 papers in training set
Top 30%
4.7%
9
Cell Reports
1498 papers in training set
Top 10%
3.9%
50% of probability mass above
10
Translational Neurodegeneration
10 papers in training set
Top 0.1%
3.1%
11
Alzheimer's Research & Therapy
57 papers in training set
Top 0.7%
2.3%
12
EMBO Molecular Medicine
95 papers in training set
Top 0.5%
2.3%
13
Scientific Reports
3612 papers in training set
Top 49%
2.1%
14
Cell Death & Disease
21 papers in training set
Top 0.2%
1.9%
15
The Journal of Neuroscience
1025 papers in training set
Top 7%
1.9%
16
Molecular Psychiatry
282 papers in training set
Top 3%
1.9%
17
International Journal of Molecular Sciences
494 papers in training set
Top 7%
1.9%
18
Brain
168 papers in training set
Top 2%
1.5%
19
Aging Cell
165 papers in training set
Top 2%
1.3%
20
Journal of Alzheimer’s Disease
50 papers in training set
Top 0.9%
1.3%
21
eneuro
439 papers in training set
Top 6%
1.1%
22
Glia
81 papers in training set
Top 1%
1.1%
23
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 37%
1.0%
24
iScience
1154 papers in training set
Top 32%
1.0%
25
Molecular Therapy
81 papers in training set
Top 2%
0.9%
26
Neurobiology of Aging
107 papers in training set
Top 1%
0.8%
27
Nature Neuroscience
252 papers in training set
Top 5%
0.8%
28
PLOS Genetics
862 papers in training set
Top 12%
0.8%
29
eLife
5828 papers in training set
Top 70%
0.6%
30
Neuron
337 papers in training set
Top 6%
0.6%